


Product Name : BnOCPA
Cat. No. : PC-49105
CAS No. : 872693-38-4
Molecular Formula : C₂₂H₂₇N₅O₅
Molecular Weight : 441.488
Target : Adenosine Receptor
Solubility : 10 mM in DMSO



Biological Activity

BnOCPA is a potent and powerful analgesic and a highly selective and potent, full agonist at human **adenosine A1 receptors** (A1Rs) with pEC₅₀ of 7.23 in a NanoBRET agonist binding assay.

BnOCPA displays 8000- and >150-fold greater efficacy at rat A1Rs (rA1Rs) than at rat A2ARs (rA2ARs) and A3Rs (rA3Rs), respectively.

BnOCPA exquisitely discriminates between native pre- and postsynaptic A1Rs in the intact mammalian CNS.

BnOCPA potently inhibited excitatory synaptic transmission in rat hippocampal slices with IC₅₀ of 65 nM.

BnOCPA demonstrates unique G_α signalling in the selective activation of G_{ob}, selectively induces canonical activation states at A1R:G_{ob}, but non-productive metastable states at other G_{αi/o} subunits.

BnOCPA (IP; 10 µg/kg) or intravenously (IV; 10 or 25 µg/kg)) is a potent analgesic without causing sedation or motor impairment.

References

Mark J Wall, et al. *Nat Commun.* 2022 Jul 18;13(1):4150.

Caution: Product has not been fully validated for medical applications. Lab Use Only!

E-mail: tech@probechem.com